Arcus Biosciences, Inc. (RCUS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$26.06
Price Target
$30.00
Target Range
$20.00 — $47.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-7.9x
Forward PEG—
Implied Growth-16.5%
Median Target$29.00
Analyst Spread90.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$20
-23.3%
Consensus
$30
+15.1%
Bull Case
$47
+80.4%
RCUS Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Arcus Biosciences, Inc. (RCUS) has a Wall Street consensus price target of $30.00, based on estimates from 18 covering analysts. With the stock currently trading at $26.06, this represents a potential upside of +15.1%. The company has a market capitalization of $2.62B.
Analyst price targets range from a low of $20.00 to a high of $47.00, representing a 90% spread in expectations. The median target of $29.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RCUS trades at a trailing P/E of -7.9x. Analysts expect EPS to grow -16.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+33.5%
Avg Forward P/E17.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AGENAgenus Inc. | $147M | $4.17 | $7.33 | +75.8% | Buy | 2.0x | 11 |
 EXELExelixis, Inc. | $11.3B | $44.42 | $45.71 | +2.9% | Buy | 13.4x | 32 |
 HALOHalozyme Therapeutics, Inc. | $7.8B | $65.87 | $78.33 | +18.9% | Buy | 8.2x | 27 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 TGTXTG Therapeutics, Inc. | $5.7B | $36.10 | $39.00 | +8.0% | Buy | 27.1x | 13 |
 IMVTImmunovant, Inc. | $5.7B | $27.84 | $45.50 | +63.4% | Buy | — | 23 |
 NKTRNektar Therapeutics | $1.7B | $84.16 | $132.83 | +57.8% | Buy | — | 33 |
 INCYIncyte Corporation | $19.5B | $97.47 | $109.50 | +12.3% | Buy | 13.0x | 44 |
 MGNXMacroGenics, Inc. | $199M | $3.15 | $6.00 | +90.5% | Buy | — | 22 |
 RVMDRevolution Medicines, Inc. | $29.0B | $147.21 | $154.80 | +5.2% | Buy | — | 22 |
Upside Potential Comparison
MGNXAGENIMVTNKTRHALOINCYTGTXRVMDSee RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRCUS — Frequently Asked Questions
Quick answers to the most common questions about buying RCUS stock.
What is the RCUS stock price target for 2026?
Arcus Biosciences, Inc. (RCUS) has a consensus 12-month price target of $30, implying 15.1% upside from $26.06. The 18 analysts covering RCUS see moderate appreciation potential.
Is RCUS a buy, sell, or hold?
RCUS has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $30 implies 15.1% upside from current levels.
Is RCUS stock overvalued or undervalued?
RCUS's current price is $26.06 with a consensus target of $30 (15.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can RCUS stock go?
The most bullish Wall Street analyst has a price target of $47 for RCUS, while the most conservative target is $20. The consensus of $30 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RCUS stock?
RCUS is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RCUS stock forecast?
The 12-month RCUS stock forecast based on 18 Wall Street analysts shows a consensus price target of $30, with estimates ranging from $20 (bear case) to $47 (bull case). The median consensus rating is "Buy".
Should I buy RCUS stock?
Wall Street analysts are optimistic on RCUS, with a "Buy" consensus rating and $30 price target (15.1% upside). 15 of 18 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RCUS price targets vary so much?
RCUS analyst price targets range from $20 to $47, a 90% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30 consensus represents the middle ground.